Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Trends Pharmacol Sci ; 41(9): 595-597, 2020 09.
Article in English | MEDLINE | ID: mdl-32624198

ABSTRACT

In cancer, suppression of protein phosphatases, such as protein phosphatase 2A (PP2A), that normally counteract kinases, contributes to aberrant signaling. Leonard et al. recently demonstrated that a novel small-molecule activator of PP2A, DT-061, selectively stabilizes a specific PP2A holoenzyme responsible for dephosphorylating critical oncogenic targets, including MYC. The 3.6-Å cryo-electron microscopy map of the heterotrimer assembly provides insight into the druggable structure of PP2A, guiding future phosphatase therapeutics.


Subject(s)
Neoplasms , Protein Phosphatase 2 , Cryoelectron Microscopy , Humans , Neoplasms/drug therapy , Protein Phosphatase 2/metabolism , Signal Transduction
2.
Cancer Discov ; 10(4): 495-497, 2020 04.
Article in English | MEDLINE | ID: mdl-32238397

ABSTRACT

In this issue of Cancer Discovery, Sodir and colleagues employ a pancreatic ductal adenocarcinoma mouse model with mutant KRAS and inducible MYC to demonstrate that MYC acts as a reversible driver of malignant tumor progression. Abrogation of MYC triggers rapid regression and disassembly of the ensemble tumor through both cancer cell-intrinsic and cancer cell-extrinsic mechanisms, providing a compelling rationale for therapeutic targeting of MYC.See related article by Sodir et al., p. 588.


Subject(s)
Adenocarcinoma , Carcinoma, Pancreatic Ductal , Pancreatic Neoplasms , Adenocarcinoma/drug therapy , Adenocarcinoma/genetics , Animals , Carcinoma, Pancreatic Ductal/drug therapy , Carcinoma, Pancreatic Ductal/genetics , Mice , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/genetics , Phenotype
SELECTION OF CITATIONS
SEARCH DETAIL
...